To determine whether Lipitor reduces stroke, compared to placebo in patients who have had a previous stroke or transient ischemic attack.
- Atorvastatin (Lipitor®)Drug
Other Names: Lipitor
- Allocation: Randomized
- Masking: Double-Blind
- Purpose: Treatment
- Endpoint: Efficacy Study
- Intervention: Parallel Assignment
Eligible patients were randomized to receive either atorvastatin 80 mg/day or placebo. Patients in both groups will be assessed at 1, 3, and 6 months, and every 6 months thereafter for 5 years.
|Type||Measure||Time Frame||Safety Issue|
|Primary||First nonfatal or fatal stroke.|
|Secondary||Stroke or TIA, major coronary event (death from cardiac causes, nonfatal myocardial infarction, or resuscitation after cardiac arrest), major cardiovascular event (stroke plus any major coronary event), acute coronary event (major coronary event or unstable angina), any coronary event (acute coronary event plus a coronary revascularization procedure, unstable angina, or angina or ischemia requiring emergency hospitalization), revascularization procedure (coronary, carotid, or peripheral), and any cardiovascular event (any of the former plus clinically significant peripheral vascular disease), individual components of the composite end points and death from any cause.|
|Primary||Time to occurrence of fatal or non-fatal stroke|
|Secondary||Time to occurrence of an acute coronary event, consisting of cardiac death, nonfatal myocardial infarction, resuscitated cardiac arrest or unstable angina.|
|Secondary||Time to occurrence of a cerebrovascular event, defined as fatal or nonfatal stroke or TIA.|
- Pfizer Lead